EDITAS MEDICINE INC

About

Editas Medicine Inc. is a clinical-stage biotechnology company focused on developing gene editing therapies using its proprietary CRISPR/Cas9 technology. The company aims to treat serious genetic diseases by editing DNA at the genomic level, with its lead programs targeting ocular disorders such as Leber congenital amaurosis. As a pioneer in the genome editing sector, Editas Medicine leverages its scientific platform to advance a pipeline of potential one-time treatments for conditions with limited medical options.